GYNECOLOGIC CANCERS

Efficacy results for the human papillomavirus (HPV) vaccine continue to be impressive, with newly reported findings showing it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.

Shitanshu Uppal, MD, discusses the need for a more comprehensive registry process for patients with cervical cancer.

Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.

Adding bevacizumab to standard platinum-based chemotherapy demonstrated a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Median overall survival was not improved with zoptarelin doxorubicin, a hybrid molecule combining an LHRH-agonist and doxorubicin, in a phase III advanced endometrial cancer trial.

Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.

Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and also less likely to develop female-specific cancers, acording to study results published in <em>Gynecologic Oncology.</em>

The combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells, according to preclinical findings published in&nbsp;<em>Precision Oncology.</em>

Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD

Bradley J. Monk, MD, discusses&nbsp;his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Shitanshu Uppal, MD, discusses&nbsp;the critical challenges to research and treatment advances in cervical and endometrial cancer.

Shana Wingo, MD, discusses&nbsp;advancements being made in the field of surgery for patients with gynecologic cancers.

Dana Chase, MD, discusses&nbsp;the potential for immunotherapy in recurrent endometrial cancer, as well as the lack of progress made thus far in endometrial cancer and other rare cancer types.

Elizabeth Swisher, MD, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Mike Janicek, MD,&nbsp;sheds light on why physicians are slow to educate patients on genetic testing, the detection of genes aside from <em>BRCA1/2</em>, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Lyndsay J. Willmott, MD, discusses how PARP inhibitor approvals have impacted clinical practice and patient outcomes and quality of life in ovarian cancer.

Heather Dalton, MD, discusses&nbsp;first-line treatment options currently available for patients, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

The IDO1 inhibitor BMS-986205 had &quot;best-in-class&quot; activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced tumors in a phase I/IIa study.

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with <em>HER2</em>-mutant advanced cancers, according to findings from the phase II SUMMIT study presented at the 2017 AACR Annual Meeting.